This is an important question in the field right now because for the patients who lack a fully HLM-matched donor, the options currently as of 2021 are cord blood transplantation using a partially HLM-matched related or unrelated donor, and we’ve been using post-transplant cyclophosphamide in this setting and which has made this procedure extremely safe and effective.
So, in a study, we embarked on asking these questions using Acute Leukemia Working Party database, looked at AML patients who underwent mismatched unrelated donor stem cell transplantation with post-transplant cyclophosphamide and compared their outcome to patients with AML who underwent a cord blood transplantation...
This is an important question in the field right now because for the patients who lack a fully HLM-matched donor, the options currently as of 2021 are cord blood transplantation using a partially HLM-matched related or unrelated donor, and we’ve been using post-transplant cyclophosphamide in this setting and which has made this procedure extremely safe and effective.
So, in a study, we embarked on asking these questions using Acute Leukemia Working Party database, looked at AML patients who underwent mismatched unrelated donor stem cell transplantation with post-transplant cyclophosphamide and compared their outcome to patients with AML who underwent a cord blood transplantation.
When we looked at in a multivariate analysis, patients who received core blood stem cell transplantation for AML had a higher risk of non-relapse mortality and relapse risk which led to worse leukemia-free overall survival compared to mismatched unrelated donor transplant to CPN with a post-transplant cyclophosphamide. There was also higher incidence of graft failure, not surprisingly, in the recipient of cord blood transplantation compared to a mismatch unrelated donor transplantation.
So, this study also shows that at least in this retrospective comparison, our outcomes are superior in individuals with AML who went in a mismatched-unrelated donor transplantation with a post-transplant cyclophosphamide compared to cord blood transplantation.